Cancer antigen 15-3 (CA 15.3)

Reference

Reference
Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, , Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study

Scoring

Total Score

A1,2,3,4,5,6,7,8,9,10,11,12,13,14

Parameter Score
1. Scale A
2. Study Population A
3. Samples A
4. Measurand A
5. Pre-Analytical A
6. Replicate Analysis A
7. Steady State A
8. Outlier Analysis A
9. Normality A
10. Variance Homogeneity A
11. ANOVA A
12. CI A
13. No of Results A
14. Concentrations A
15. Total Score A1,2,3,4,5,6,7,8,9,10,11,12,13,14
Comment

Item Details

Parameter Score
Matrix Serum
Measurand Cancer antigen 15-3 (CA 15.3)
Unit ku / L
Overall Analytical Principle Method Immunoassay; Not specified
Number of Subjects 42
Number of Subjects included in BV estimation 42
Ethinicity Caucasian
Age Mean / Median
Age Min 21.0
Age Max 69.0
Age SD
Number of Males
Number of Females 42
State of Well Being
Healthy (excl pregnant)
Diseases
Study Duration Length 10
Study Duration Units Week
Sampling Intervals, e.g. X sample(s) per Interval Unit 1
Interval Units Week
Sampling Times Start Time: 08:00
End Time: 10:00
Number of Samples 10
Average Number of Samples Used for BV Estimation 10.0
Average Number of Replicates 2.0
Estimates of CVi 5.0
Calculated Confidence Intervals of CVi Lower: 4.63, Upper: 5.42
Estimates of CVg 39.6
Calculated Confidence Intervals of CVg Lower: 32.64, Upper: 50.35
Analytical CV 2.2
Calculated Confidence Intervals of Analytical CV Lower: 2.06, Upper: 2.36
Measurand Mean 15.3
Measurand Min 14.8
Measurand Max 15.8
Measurand SD

Coding